Invokana ®, the first in a new class of frontline treatments for type 2 diabetes, was approved in 2013 and quickly reached blockbuster status. Other drugs in the class include Invokamet ®, Jardiance ®, Xigduo XR ®, Farxiga ®, and Glyxambi ®. These drugs, known as SGLT2 inhibitors, are intended to improve glycemic control in patients with type 2 diabetes by blocking the absorption of glucose in the kidneys.
The problem is that SGLT2 inhibitors can lead to the development of diabetic ketoacidosis, a serious condition that can result in cerebral edema, pulmonary edema, heart attacks, strokes, cardiac dysrhythmia, non-specific myocardial injury, diabetic retinopathy, severe dehydration, coma and death. The FDA recently took notice of these significant health risks and issued a safety announcement that warned of serious side effects potentially resulting from treatment with SGLT2 inhibitors.
Type 2 diabetes is tough enough. Bad treatment options should be exposed and fair compensation for injuries should be issued to victims of SGLT2 inhibitors. If you have type 2 diabetes and have been treated with Invokana or other SGLT2 inhibitors and thereafter suffered diabetic ketoacidosis or other life-threatening injuries, call us 855-LAW-2020 today. We will connect you with the counsel and resources necessary to answer your questions and work on your behalf to help you receive a fair and just settlement.
BCN: “Know Your Attorney. Know Your Options”